Kornimate/medical-research-clean huggingface dataset:
prospective study to validate ablation parameters with mri based scar for left atrial ablation

Conditions: Atrial Fibrillation

Summary: one of the goals of an ablation procedure is to create scarring of cardiac tissue. not all ablations result in scar tissue. advances in technology have improved scarring but ideal parameters that result in scar tissue are still not completely clear and there is great variability in the parameters used. theoretically, intense ablation can always create scar tissue but is also likely to create more complications such as cardiac perforations. the investigator recently published another retrospective study looking at ablation parameters that reliably result in scar tissue but it had its limitations as it was retrospectively done. this is a prospective study to validate the parameters that result in long term scarring. mri has long been used to visualize ablation scar tissue. so in this study patients undergoing, initial left atrial ablation for atrial fibrillation as standard of care will undergo a 3 month post ablation mri and that will be used to validate the ablation parameters.

a critical step to improve atrial fibrillation (af) ablation broadly is to minimize interoperator variability. visitag surpoint calculated a marker tag index value by combining contact force, power setting, and duration of energy delivered. use of visitag surpoint has accurately predicted sites of pulmonary vein reconnection and regional changes in late gadolinium enhancement (lge) and t2 (edema) intensity 24 hours post ablation. prospective use of the ablation index improves first pass pulmonary vein isolation and 1-year freedom from atrial tachyarrhythmias compared to conventional treatment. there remains a paucity of data regarding if ablation guided by index values and visitag surpoint results in durable scar formation in humans in general and compared to conventional approaches. in addition, the relative contribution of the components of visitag surpoint impact scar formation in-vivo and across a broad diversity of atrial anatomies. such data are critical in patients that present with various degrees of atrial myopathies, arrhythmia substrate, and anatomies.

Eligibility criteria:
inclusion criteria: * paroxysmal or early persistent af (continuous af duration less than 3 months and chadsvasc great than or equal to 2). * first time ablation for af * agreeable to a 3 month mri exclusion criteria: * claustrophobic (unable to undergo mri) * having undergone prior left atrial ablation including at or atypical flutter * metal implants that preclude getting an mri * egfr \< 30

Keywords: atrial fibrillation ablation
emg to detect and monitor freezing of gait among people with parkinson's disease

Conditions: Evaluation of Muscle Contraction in People With PD

Summary: the main goal of this study is to evaluate, via emg (electromyography) system, the muscle activity in the lower limbs, to understand the contribution of the muscle activity to fog (freezing of gait) in parkinson's patients. the phenomenon of fog appears in advanced cases of parkinson's disease (pd) and can lead to an increased risk of falls. there are several approaches claiming that there is abnormal activity in the calf muscles and the freezing events in parkinson's patients. in the clinic, monitoring fog is done subjectively, usually through observations or through questionnaires. as a result, the information about the phenomenon may be biased and insensitive. with an electromyographic monitor (emg), objective information about the muscular activity during normal walking and during unusual events can be obtained.

the subject will arrive independently at the tel aviv medical center. after explaining the course of the study and signing a consent form, the subject will be administered the moca questionnaire to assess the cognitive state. during this session, the patient will undergo gait evaluation using motion sensors and an emg device. this meeting will last up to an hour, according to the following breakdown: explanation of the test (10 min) preparing the skin (light disinfection with alcohol) for emg adhesion (10 min.) performing of the test (20 minutes) summary and discharge (5 min).

Eligibility criteria:
inclusion criteria for patients: 1. men and women aged 40-89. 2. patients with idiopathic parkinson's disease according to the diagnosis of a neurologist, who are able to walk with or without a walking aid for at least 5 minutes. 3. 21 or above in moca test. 4. people who gave their written and oral consent to participate in the study. inclusion criteria for healthy people: 1. men and women aged 40-89. 2. 24 or above in moca test. 3. without a neurological, cardiovascular or orthopedic disorder, which could affect the normal walking pattern, and all within the researcher's decision. criteria for exclusion from the experiment: 1. the patient has serious side effects that are not suitable for continuing in the study. 2. the patient does not wish to continue his participation in the study. exclusion criteria for parkinson's patients: 1. neurological or other psychiatric disorder (such as msa, psp, after a stroke with neurological signs, dementia diseases, clinical depression) at the researcher's decision. 2. history of head injury - traumatic brain injury or cerebrovascular accident (cva) 3. this study will not include pregnant women and children.
study of mk-6552 in participants with narcolepsy type 1 (mk-6552-004)

Conditions: Narcolepsy

Summary: the purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (pk), and pharmacodynamics (pd) of mk-6552 in participants with narcolepsy type 1 (nt1). part 1 will evaluate safety, tolerability, and pk of mk-6552 after administration of ascending doses in a single day to support a dose level decision for part 2. part 2 will investigate the pd of mk-6552 after single-day and multiple-day administration. participants who complete part 1 and demonstrate that they are able to tolerate at least one dose level of mk-6552 will participate in part 2.


Eligibility criteria:
inclusion criteria: * has a diagnosis of nt1, including a valid polysomnography within the previous 5 years and a current diagnosis of nt1 for at least 6 months based on criteria established by the international classification of sleep disorders- third edition, or diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) \[american psychiatric association 2013\] * is positive for hla-dqb1\*06:02 allele supporting a diagnosis of nt1 * has a baseline history of unequivocal cataplexy prior to initiation of anti-cataplexy medications * reports a total sleep time of \> 6 hours on at least 4 out of 7 nights each week within the 4 weeks prior to screening visit exclusion criteria: * has history of or current hypertension * has underlying cardiovascular or cerebrovascular conditions in which an acute rise in blood pressure would pose a clinical concern, including but nor limited to aneurysms or arteriovenous malformations * has a history of renal or hepatic impairment * has a history of cardiac ischemia or cerebral ischemia including but not limited to history of stroke, transient ischemic attack, or transient global amnesia * based on clinical interview and responses on the columbia-suicide severity rating scale, is at imminent risk of self-harm or of harm to others in the opinion of the investigator * mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years * history of cancer (malignancy) * has a history of any of the following sleep disorders: obstructive sleep apnea (osa) defined as an apnea hypopnea index \> 15 per hour per the american academy of sleep medicine alternate criteria, primary insomnia (within the past 6 months), circadian rhythm sleep disorder, shift work sleep disorder (within the past 6 months), clinically significant parasomnia at the discretion of the investigator * has a history of seizure disorder, clinically significant head trauma, or past invasive intracranial surgery or clinically significant dementia * positive test(s) for hepatitis b surface antigen, hepatitis c antibodies, or human immunodeficiency virus
internet-delivered group counseling for chronic tinnitus

Conditions: Tinnitus, Subjective

Summary: in the treatment of chronic tinnitus, psycho-education plays an import role to provide more insights into the symptoms of tinnitus. however, the need for e-health is increasing. as such, it is important to investigate if these psycho-education sessions can be delivered online, with the same efficacy compared to the traditional face-to-face delivery.


Eligibility criteria:
inclusion criteria: * patients with subjective, chronic tinnitus exclusion criteria: * enrollment in other tinnitus treatments simultaneously at the time of the intervention

Keywords: tinnitus treatment delivery method psycho-educational counseling internet-based
domiciliary physiotherapy in women undergoing treatment for breast cancer radiation

Conditions: Frozen Shoulder,; Shoulder Pain

Summary: to observe the effect of domiciliary physiotherapy on the upper limb applied during the period of radiotherapy in women submitted to surgical and radiotherapy for breast cancer. the parameters evaluated were: shoulder range of movement (rom) and arm circumference. there was significant difference between the ipsilateral and contralateral limbs for flexion, abduction and external rotation. there was no difference in perimetry in either group


Eligibility criteria:
inclusion criteria: * be diagnosed with unilateral breast cancer; * be submitted to surgical and radiation treatment as part of the treatment for breast cancer. exclusion criteria: * patients with neurological or orthopedic diseases that could impair the upper limb movements * bilateral breast cancer; * prior thoracic radiotherapy; * presence of distant metastasis.

Keywords: breast cancer, radiotherapy, physical therapy, upper limb
lay-user trial of the iglucose blood glucose monitoring system

Conditions: Diabetes Mellitus

Summary: evaluation of the iglucose blood glucose monitoring system in the hands of lay users

a non-randomized, prospective study of recruited subjects with diabetes. subjects will include those with type i or type ii diabetes of various duration and those who are naive to self-testing of blood glucose. subjects will use provided instructions-for-use to undergo self-training on the use of the device and will then self-test their blood glucose level. results will be compared to those obtained by a lab glucose analyzer.

Eligibility criteria:
inclusion criteria: * be 12 years of age and older * have pre-existing diagnosis of diabetes * be able to read and understand english * agree to participate in the study * be able and willing to provide informed consent exclusion criteria: * do not meet inclusion criteria * with hemophilia or any other bleeding disorder * with any condition which in the opinion of the investigator may place the subject or site staff at excessive risk * with physical condition/limitation preventing the use of smbg on their own

Keywords: diabetes, blood sugar
levator resection with3 point fixation versus 2 point fixation tucking for congenital ptosis

Conditions: Congenital Ptosis

Summary: to evaluate the surgical effect of levator aponeurosis resection versus two point fixation levator aponeurosis tucking for congenital ptosis

target population for the study is children under twelve years old presenting to ophthalmology clinic at cairo university specialized pediatric hospital with congenital ptosis. patients will be randomly divided into two groups first group (a) will contain 20 patients who will undergo standard levator aponeurosis resection second group (b) will contain 20 patient who will undergo two point fixation levator tucking

Eligibility criteria:
inclusion criteria: 1. unilateral or bilateral simple isolated congenital ptosis. 2. levator function more than 4mm exclusion criteria: 1. congenital ptosis associated with other ocular syndromes. 2. recurrent ptosis following any attempt for repair. 3. traumatic ptosis or acquired ptosis 4. -ve bell's phenomenon.

Keywords: levator resection levator tucking fair levator function eyelid contour
prospective randomized study on clinical effectiveness of carvo-tricuspid isthmus block in patients with paroxysmal atrial fibrillation

Conditions: Atrial Fibrillation

Summary: prospective randomized study on clinical effectiveness of carvo-tricuspid isthmus (cti) block in patients with paroxysmal atrial fibrillation (paf) will be performed. study will be composed with two arms including 4 pulmonary vein isolation and pulmonary vein isolation with cti block. after that all patients will be followed up by hrs(heart rhythm society) 2010 expert consensus guideline.


Eligibility criteria:
inclusion criteria: * patients with documented af * drug refractory af * non-valvular af * no structural cardiac disease * no intracardiac thrombi in cardiac ct and tee exclusion criteria: * permanent af refractory to electrical cardioversion * la size \>55 mm as measured by echocardiography * af with valvular disease * associated structural heart disease other than left ventricular hypertrophy * prior af ablation.

Keywords: atrial fibrillation atrial flutter catheter ablation cavo-tricuspid isthmus block
treatment of atfl tears with prp

Conditions: Soft Tissue Healing

Summary: prp will enhance atfl tears healing by time and quality.


Eligibility criteria:
inclusion criteria: * athletes 18-30 years old 1st sprain within 3 days from injury exclusion criteria:

Keywords: prp atfl
impact of intravascular fluid resuscitation and whole blood viscosity

Conditions: Cerebral Aneurysm

Summary: after obtaining approval from the institutional review board of our institution, written informed consent is obtained from patients undergoing interventional cerebral aneurysm coiling procedure are enrolled in this prospective study and randomly allocated into one of two groups: group-c (n=15) and group-hes (n=15). all recruited patients will be given patient identification number (pin) for the present study of 01-30 according to their order of interview and recruitment. investigators will prepare 15 yellow and 15 green cards, which will be inserted in 20 thick-paper envelopes. then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (envelop number). after printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department. according to the color of the card, attending anesthesiologists will give crystalloid for yellow card or hes for green cards, respectively, to maintain stroke volume variation lesser than 15 during volume controlled ventilation (8 ml/kg tidal volume) of o2/air mixture. patient data and statistical analyses: patients demographic data, whole blood viscosity, pao2, fio2, hemoglobin, urine amount, s-glucose will be obtained


Eligibility criteria:
inclusion criteria: * patients undergoing coiling embolization procedure due to cerebral aneurysm * patients provided a written informed consent. * patients with preoperative serum hemoglobin concentration \>13 g/dl (male) and \>12 g/dl (female) * patients with pao2/fio2 ratio \>150 exclusion criteria: * patients with history of anemia, dyspnea, active infection. * patients with endocrine disease * patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, anti-platelet drug, anti-fibrinolytic agents or recombinant human erythropoietin, or undergoing acute normovolemic hemodilution.

Keywords: cerebral aneurysm, coiling embolization, blood viscosity
q fever and auto-immunity

Conditions: Q Fever; Auto-Immunity

Summary: the ihu mediterranean infection is national reference centre for q fever. coxiella burnetii is the bacteria responsible of this infection. the bacterium coxiella burnetii infection is associated with secretion by the body both many antibodies against the bacteria but also against certain cells of the body (autoantibodies). these autoantibodies may have no effect or be associated with specific symptoms. anti-phospholipid antibodies are especially prevalent in the q fever. apart from this infection, they are associated with thrombocytopenia, obstetric complications, thrombosis and heart valve damage. these conditions have also been described as complications during q fever. in a retrospective preliminary work on q fever, we have shown that the presence of high levels of igg anti-cardiolipin was associated with the presence of valvular and the evolution to endocarditis. such associations have a therapeutic involvement and must therefore be confirmed. indeed, if these associations were confirmed, a trans-esophageal ultrasound could be systematically proposed to patients with valvular disease of trans-thoracique ultrasound but igg anticardiolipin high levels. other special attention could be given to patients with high autoantibodies.


Eligibility criteria:
inclusion criteria: * patients with a current or former q fever diagnosis * patient \> or = 18 years old. * patient who does not declined to have his medical records reviewed for research. * patient with health insurance. exclusion criteria: * minor patient (\<18 years ) * adult patient under guardianship . * patient deprived of liberty or judgment. * patient refusing to sign the informed consent form .
allograft, a study to evaluate the renal protective effects of losartan (0954-222)(completed)

Conditions: High Blood Pressure

Summary: to demonstrate that losartan (+ conventional therapy) compared to placebo (+ conventional therapy) will reduce the number of rt patients who experience histological lesions of chronic allograft nephropathy


Eligibility criteria:
inclusion criteria: * patients with end stage chronic renal failure, four to eight week after receiving a first or a second renal transplant from a dead donor. in the case of a second transplant the survival of the first graft must has been 6 month or more * patients must have a serum creatinine \* 2 at visit 1 and 2. results must be within 25% of each other. the baseline period may be extended until four more weeks to obtain an additional serum creatinine if one of the first two serum creatinine results do not qualify * patients with hypertension must have a sitting blood pressure \< 200/110 mmhg at the time of randomization * normotensive patients must have a sitting systolic blood pressure \>100 mmhg at the time of randomization exclusion criteria: * hyperimmunized patients at the transplant time or in the previous 6 month, with a pra of 50 % * patients with evidence of advanced liver disease * serum potassium \ 5.5 meq/l * history of allergy to losartan * other factors which may affect participation (e.g., significant concurrent or life limiting disease such as cancer in the last five year except skin neoplasias, mental or legal incapacitation, drug or alcohol abuse within the last 2 years, extensive travel planned in the next 3 years, investigative drug trial within the last 4 weeks) * patients with disseminated or localized active infectious disease, at the time of transplant * acute graft rejection in the grade iii of banff classification * patients with double-transplant (reno-pancreatic) * patients with heart failure or history of myocardial infarction requiring ace inhibitor or aiia therapies. presence or known history of hemodynamically significant obstructive valvular disease or hypertrophic cardiomyopathy * renal graft artery stenosis. an eco-doppler test must be performed in order to exclude a graft artery stenosis * pregnant or nursing women * chronic use of nsaids * major psychotropic agents such as phenothiazines are not permitted, use of lithium is not permitted
radiofrequency ablation during surgery in treating patients with non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: radiofrequency ablation uses high-frequency electric current to kill tumor cells. combining radiofrequency ablation with surgery may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage i or stage ii non-small cell lung cancer.

objectives: * determine the acute effects of intraoperative radiofrequency tumor ablation (rfa) in patients with resectable non-small cell lung cancer. * determine the treatment-related toxicity in patients treated with this therapy. * determine the dimensions of the rfa lesion produced by the ablation procedure in these patients. outline: patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection. projected accrual: a maximum of 20 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of malignant non-small cell lung cancer (nsclc) * intraoperative needle biopsy confirmation allowed * resectable disease (stage i or ii) * all tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection * medically fit to undergo lung resection patient characteristics: age: * over 18 performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * not pregnant or nursing prior concurrent therapy: biologic therapy: * no prior or concurrent biologic therapy chemotherapy: * no prior or concurrent chemotherapy endocrine therapy: * no prior or concurrent endocrine therapy radiotherapy: * no prior or concurrent radiotherapy surgery: * see disease characteristics other: * no other prior therapy for nsclc

Keywords: stage i non-small cell lung cancer stage ii non-small cell lung cancer